⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ACRV News
Acrivon Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
ACRV
Form 8-K
sec.gov
ACRV
Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
globenewswire.com
ACRV
Key Opinion Leader (KOL) Panel to Discuss Acrivon’s ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress
globenewswire.com
ACRV
Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory
globenewswire.com
ACRV
Registration Momentum Builds Across the Oncology Pipeline
globenewswire.com
ACRV
KPTI
ERAS
ONCY
INCY
Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment
prnewswire.com
ACRV
BNTX
IBRX
ONCY
MAIA
Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress
globenewswire.com
ACRV
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11
globenewswire.com
ACRV
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
globenewswire.com
ACRV